

Chou, Ting-Chao[Get A Badge](#)[ResearcherID Labs](#)

ResearcherID: B-4111-2009


Other Names: T.C. Chou; TC Chou

URL: <http://www.researcherid.com/rid/B-4111-2009>[My Institutions \(more details\)](#)

Primary Institution: Memorial Sloan-Kettering Cancer Center

Sub-org/Dept:

Role: Researcher (Academic)

My Publications**My Publications (273)**[View Publications](#)[Citation Metrics](#) ►[ResearcherID labs](#)[Create A Badge](#)[Collaboration Network](#)[Citing Articles Network](#)

Total Articles in Publication List: 273

Articles With Citation Data: 259

Sum of the Times Cited: 17229

Average Citations per Article: 66.52

h-index: 58


Last Updated: 01/31/2016
12:51 GMT

Trends of Drug Combination Methods for Synergy Determination, 1900-2015*


Method, Main Theory and Reference Source	Trend of Citation				Total Citations Since Publication	Average Citations per year
	2011	2012	2013	2014		
A. Chou, TC & Talalay, P Adv. Eng. Regul. 1984; 22:27-55	[CI Method]	289	257	283	325	3,648
B. Chou, TC Pharmacol. Rev. 2006;58: 621-681	[CI Method]	119	146	158	205	1,066
C. Berenbaum, MC Pharmacol. Rev. 1989; 41: 93-141		42	37	46	42	912
D. Bliss, CI Ann. Appl. Biol. 1939; 26: 585-615		48	70	68	76	705
E. Steel GG & Peekham MJ Int. J. Radiat. Oncol. BioPhys. 1979; 5: 85-91		16	22	14	15	680
F. Greco, WR et al Pharmacol. Rev. 1995; 47: 331-385		33	38	56	56	614
G. Chou TC Cancer Res. 2010; 70: 440-446	[CI Method]	41	75	123	174	631
H. Elion GB, Singer S & Hitchings GH J. Biol. Chem. 1954; 208: 477-488		3	9	4	4	449
I. Tallarida, RJ J. Pharmacol. Exp. Ther. 2001; 298: 865-872		26	26	34	34	353
J. Prichard, MN & Shipman C Jr Antiviral Res. 1990; 14: 181-205		16	18	16	24	342
K. Webb J.L. Acad. Press. 1963; 1: 66-79, 488-512		8	9	12	6	#262
L. Loewe, S Pharmacol. Rev. 1957; 9: 237-242		3	0	4	5	118

*Based on Thomson Reuters Web of Science All Database Collection, as of January 15, 2016.

#Based on Google Scholar Citations, as of January 15, 2016.



Quantitative-Analysis of Dose-Effect Relationships- The Combined Effects of Multiple-Drugs or Enzyme-Inhibitors [The Combination Index Theorem]




Source: ISI Web of Knowledge™, www.thomsonscientific.com

CHOU, TC; TALALAY, P
ADVANCES IN ENZYME REGULATION, 22: 27-55, 1984

Times Cited: 4,595 (3,658 In 693 Journals*)

(*Among The Most Broadly Cited *Theoretical Papers* by Journals of All Time)

“Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies”




CHOU TC, PHARMACOLOGICAL REVIEWS, 58: 621-681, 2006

Times Cited: 1,498 (1,072 in 404 Journals)*

**[The Most Cited / the Broadest Cited Pharmacology Article in the World by Journals Since 2006]*

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. *Chou. T.C. Cancer Research 70: 440-446, 2010*



Source: Web of Science™, <http://thomsonreuters.com/scholarly-scientific-research/>

Cited by: 869 (640) papers in 237 Bio-medical Journals in 5 Years.


Indexed in
MEDLINE!

Integrative Biology

Quantitative biosciences from nano to macro

www.rsc.org/biology

Volume 3 | Number 5 | May 2011 | Pages 501–594



ISSN 1757-9694

RSC Publishing

PERSPECTIVE

Chou

The mass-action law based algorithms for quantitative econo-green bio-research



1757-9694(2011)3:5;1-S

Blogs Home

Integrative Biology Blog

Integrative Biology Blog RSS 

HOT: one equation to lead the way to greener biomedical sciences

05 May 2011

By [Francesca Burgoyne](#)



In this HOT Perspective article **Ting-Chao Chou** from the [Memorial Sloan-Kettering Cancer Center, New York](#) presents his vision for a new era of smarter, greener biomedical research and drug discovery.

The algorithm of the **median-effect equation** based on the **mass-action law**, along with experimental design and computer simulation, should allow a significant reduction in the number of data points required to yield useful bioinformatics on the relationship between dose and effect. He poses that a theoretical minimum of a mere two data points are required to construct dose-effect curves – if they are accurately determined. This unified theory, he believes, should pave the way for more efficient, cost-effective research and ethical clinical trials.

This HOT article received glowing reports from our referees and is featured on the front cover of our latest issue – [Issue 5](#). Why not take a look – it's currently **free** to access:

The mass-action law based algorithms for quantitative econo-green bio-research

Ting-Chao Chou

Integr. Biol., 2011, **3**, 548-559 [Published by Royal Society of Chemistry, Cambridge, UK]

DOI: 10.1039/C0IB00130A 6177480



Synergy

International Journal for Synergy Research in Life Sciences

CONTENTS

Editorial	
<i>G. Ulrich-Merzenich, N. Sucher</i>	
Frequently asked questions in drug combinations and the mass-action law-based answers	
<i>T.-C. Chou</i>	
From additivity to synergism – A modelling perspective	
<i>C. Ritz, J.C. Streibig</i>	
Searching for synergy <i>in silico</i>, <i>in vitro</i> and <i>in vivo</i>	
<i>N.J. Sucher</i>	
Overcoming of P-glycoprotein-mediated multidrug resistance of tumors <i>in vivo</i> by drug combinations	
<i>M. Saeed, M. Zeino, O. Kadioglu, M. Volm, T. Efferth</i>	
Combination screening of synthetic drugs and plant derived natural products –Potential and challenges for drug development	
<i>G.S. Ulrich-Merzenich</i>	
Status quo and future developments of combinations of medicinal products	
<i>J.K. Schweim, H.G. Schweim</i>	
Novel options of complex combinatory screening by digital dispensing technology	
<i>M. Biegger, M. Counsell, F. Gyger, B. Maurer, E. Wärsten, B. Merzenich</i>	
A personalised medicine drug sensitivity and resistance testing platform and utilisation of acoustic droplet ejection at the Institute for Molecular Medicine Finland	
<i>J. Saarela, E. Kulesskiy, K. Laamanen, T. Pemovska, V. Pietiläinen, S. Pottdar, C. von Schantz-Fant, L. Turunen, P. Östling, K. Wennerberg</i>	
The development of fixed drug combinations –The example of Aspirin® Complex	
<i>U. Gessner</i>	
Effectiveness versus toxicity: How to assess combinations?	
<i>O. Kalber, H. Abdel-Aziz, D. Schrank</i>	


Journal Inauguration Announcement

September 23, 2014

Mip-Tec, Basel, Switzerland

Available online at www.sciencedirect.com

ScienceDirect






Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/synres



REVIEW PAPER

Frequently asked questions in drug combinations and the mass-action law-based answers



Ting-Chao Chou*

Molecular Pharmacology & Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

Received 3 July 2014; accepted 25 July 2014

KEYWORDS

Median-effect equation;
Combination index;
Dose-reduction index;
Isobologram;
Polygonogram;
Computer synergy simulation

Summary Drug combinations have been widely used in the treatment of the most dreadful diseases, such as cancer and AIDS. In the search for synergistic combinations for therapy, numerous articles have been published during the past century. However, the term “synergy” has at least 20 different definitions in literature but none supports others. The confusion on synergy claims has far reaching consequences in biomedical research, drug discovery and development, regulation, and medical care of patients. This article reviews the current status and enlists the frequently occurred pit-falls, misconceptions and common errors in drug combination studies. The questions and issues are contemplated to be answered and clarified with the physico-chemical algorithms of the mass-action law, specifically with the unified theory of the median-effect equation and its combination index theorem for drug combinations. The derived theory, algorithm and its computer simulation lead to a quantitative indexed bioinformatics, and econo-green bio-research using small number of data points.

© 2014 Elsevier GmbH. All rights reserved.